Evgen Pharma PLC (LON:EVG) shares surged said 11% to 13.75p after it got the all-clear to start a trial of its SFX-01 lead candidate.
Evgen said all necessary regulatory approvals have now been received for the STAR trial, a Phase II/III trial to investigate whether SFX-01 can reduce the severity, or prevent the onset of, acute respiratory distress syndrome in patients with suspected COVID-19.
“We hope that the outcome of this trial will lead to an additional treatment for COVID-19 patients and that SFX-01 could play a big part in managing the current pandemic,” said Huw Jones, the chief executive officer of Evgen.
Sensyne Health PLC (LON:SENS) jumped 7.6% to 99.5p after it agreed to a research collaboration with US drugs giant, Bristol Myers Squibb.
The collaboration will see Sensyne deploy its artificial intelligence and machine learning technology to help better understand certain rare blood diseases.
Work will focus on Myeloproliferative Neoplasms to assess the progression of these blood cancers that are characterised by the over-production of white or red cells, or platelets.